Prostatic Neoplasms Clinical Trial
Official title:
Non-invasive Imaging of Tumor Hypoxia With [18F]HX4 Positron-Emission-Tomography (PET): A Phase II Trial
Regulation of tissue oxygen homeostasis is critical for cell function, proliferation and survival. Evidence for this continues to accumulate along with our understanding of the complex oxygen-sensing pathways present within cells. Several pathophysiological disorders are associated with a loss in oxygen homeostasis, including heart disease, stroke, and cancer. The microenvironment of tumors in particular is very oxygen heterogeneous, with hypoxic areas which may explain our difficulty treating cancer effectively. Prostate carcinomas are known to be hypoxic. Increasing levels of hypoxia within prostatic tissue is related to increasing clinical stage, patient age and a more aggressive prostate cancer. Several researches indicated that hypoxia might also play a role in esophageal cancer. In glial brain tumors, hypoxia is correlated with more rapid tumor recurrence and the hypoxic burden in newly diagnosed glioblastomas is linked to the biological aggressiveness. In brain metastases CA-IX expression (a marker for hypoxia) is correlated to the primary non-small cell lung carcinomas. Hypoxia enhances proliferation, angiogenesis, metastasis, chemoresistance and radioresistance of hepatocellular carcinoma. The hypoxic markers HIF-1α, VEGF, CA-IX and GLUT-1 were all over expressed in colorectal cancer and its liver metastases. Based on literature, hypoxia in tumors originating or disseminated to prostate, esophagus, brain and rectum cancer will be studied in this trial.
Rationale: Non-invasive imaging of hypoxia with the aid of PET-scans could help to select the
patients having a hypoxic tumor, who could be treated with specific anti-hypoxic treatments.
The added value of additional anti-hypoxic treatments depends on the presence of hypoxia and
adequate patient selection. Several 2-nitroimidazoles, labeled with Fluor-18 (18F) have
already been used in patients to identify hypoxia. However, suboptimal image quality and
unpredictable kinetics limit their use. In extensive pre-clinical models and clinical trials
the combination of HX4 labeled with 18F showed to be a promising and non-toxic new probe to
determine hypoxia. With this tracer the proportion of hypoxic tumors in several cancer types
will be verified.
Objective: Determine if tumor hypoxia can be accurately visualized with [18F]HX4 in solid
lesions.
Study design: Phase II, several solid tumors, single-centre, imaging, non-randomized, open
label trial.
Study population:
Main patient characteristics are:
- Histological/cytological confirmed carcinoma of de esophagus, rectum or prostate or
radiological suspicion for Grade IV glioma (primary brain tumor) or brain metastases.
- WHO performance status 0 to 2
- Adequate renal function (calculated creatinine clearance at least 60 ml/min).
- Capable of complying with study procedures
Main intervention: In addition to standard clinical care patients receive two additional PET
scans after injection with the hypoxia tracer [18F]HX4.
Main study parameters/endpoints:
- Visualization and quantification of tumor hypoxia with [18F] HX4 PET imaging
- Exploring the potential relationship between [18F] HX4 uptake with local and
locoregional tumor recurrence and survival
- Correlation of hypoxia imaging with blood hypoxia markers
- Correlation of hypoxia imaging with tumor tissue biomarkers
- Evaluation of tumor hypoxia changes during treatment.
- Spatial correlation of [18F] HX4-PET with imaging pre-treatment (if present from routine
clinical practice)
- Spatial correlation of [18F] HX4-PET with imaging three months after treatment (if
present from routine clinical practice)
- Quantitative and qualitative correlation of [18F] HX4-PET obtained before treatment and
two weeks into treatment
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness:
The radiation burden due to [18F]HX4 is similar to that encountered in many routine nuclear
medicine procedures e.g. [18F]FDG PET. Administration of [18F]HX4 presents no known risks. In
previous studies (healthy volunteers, phase I, phase II) no adverse effects were observed.
There are no immediate potential benefits except the satisfaction to participate to improve
of knowledge.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04964271 -
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
|
||
Completed |
NCT02546908 -
A Registry of Participants With Prostate Cancer in Asia
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT01683994 -
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
Completed |
NCT02364531 -
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
|
||
Completed |
NCT01929655 -
Japanese BAY88-8223 Monotherapy Phase II Study
|
Phase 2 | |
Active, not recruiting |
NCT05022849 -
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
|
Phase 1 | |
Completed |
NCT03261999 -
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
|
Phase 3 | |
Terminated |
NCT04907227 -
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
|
Phase 3 | |
Active, not recruiting |
NCT03587285 -
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02217566 -
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04101305 -
Measurement of Circulating Tumor Cells in Prostate Cancer
|
||
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Terminated |
NCT03066154 -
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
|
Phase 1 | |
Withdrawn |
NCT02905201 -
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
N/A | |
Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
Terminated |
NCT01420965 -
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
|
Phase 2 | |
Completed |
NCT01441713 -
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
|
N/A |